What criteria for pharmaceuticals reimbursement?

Autor: C Le Pen, G Priol, H Lilliu
Rok vydání: 2003
Předmět:
Zdroj: The European Journal of Health Economics. 4:30-36
ISSN: 1618-7601
1618-7598
DOI: 10.1007/s10198-002-0145-2
Popis: The criteria for the registration of new drugs may differ from the criteria for drug reimbursement. In 2000 the French government entrusted the French Medicines Agency with determining the “medical service rendered” (MSR) for each reimbursable drug.The goal was to determine which drugs could be classified with an “insufficient” MSR and therefore should be taken out of the scope of health insurance.We analyze the concepts and methods used for this evaluation and the kind of results that are obtained.We collected data on the result of MSR classification and the criteria used to perform this classification (efficacy-security, severity of the disease,place in the therapeutic strategy, existence of therapeutic alternative, public health value) for a sample of 1453 drugs belonging to five therapeutic areas.We used statistical analysis to determine what were the most influential criteria. Only two criteria – efficacy and disease severity – suffice to very largely explain the MSR classification. The other criteria contribute little added value.Some of these criteria clearly suffer from a lack of clarification, leading to different interpretations according to therapeutic class or even according to drug or drug family. The evaluation procedure differs between therapeutic classes, at least at intermediate MSR levels.Analysis of the French experience with MSR shows that the evaluation procedure has not succeeded in completely breaking away from the traditional logic of the marketing authorization and registration, as witnessed by the importance of the “efficacy/safety” criterion, the absence of an economic criterion, and the vagueness of the “public health value” criterion, which one would have thought would instead be decisive.
Databáze: OpenAIRE
Externí odkaz: